SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Wang, L.
Right arrow Articles by He, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, L.
Right arrow Articles by He, L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia

Lei Wang

Bio-X center, Shanghai Jiao Tong University, Shanghai, China, Institute for Nutritional Science, Shanghai Institute of Biological Sciences, Chinese Academy of Sciences, Shanghai, China

Lan Yu

Bio-X center, Shanghai Jiao Tong University, Shanghai, China, Institute for Nutritional Science, Shanghai Institute of Biological Sciences, Chinese Academy of Sciences, Shanghai, China

Ai-Ping Zhang

Bio-X center, Shanghai Jiao Tong University, Shanghai, China, Institute for Nutritional Science, Shanghai Institute of Biological Sciences, Chinese Academy of Sciences, Shanghai, China

Chao Fang

Bio-X Center, Shanghai Jiao Tong University, Shanghai, China, Institute for Nutritional Science, Shanghai Institute of Biological Sciences, Chinese Academy of Sciences, Shanghai, China

Jing Du

Bio-X center, Shanghai Jiao Tong University, Shanghai, China, Institute for Nutritional Science, Shanghai Institute of Biological Sciences, Chinese Academy of Sciences, Shanghai, China

Niu-Fan Gu

Shanghai Institute of Mental health, Shanghai, China

Sheng-Ying Qin

Bio-X center, Shanghai Jiao Tong University, Shanghai, China, Institute for Nutritional Science, Shanghai Institute of Biological Sciences, Chinese Academy of Sciences, Shanghai, China

Guo-Yin Feng

Shanghai Institute of Mental health, Shanghai, China

Xing-Wang Li

Bio-X center, Shanghai Jiao Tong University, Shanghai, China, Institute for Nutritional Science, Shanghai Institute of Biological Sciences, Chinese Academy of Sciences, Shanghai, China

Qing-He Xing

Bio-X center, Shanghai Jiao Tong University, Shanghai, China, Institute for Nutritional Science, Shanghai Institute of Biological Sciences, Chinese Academy of Sciences, Shanghai, China, xinqinghe{at}sjtu.edu.cn

Lin He

Institute for Nutritional Science, Shanghai Institute of Biological Sciences, Chinese Academy of Sciences, Shanghai, China, NHGG, Bio-X center, Shanghai Jiao Tong University, Shanghai, China, helin{at}bio-x.cn

The object of this study is to assess 1) the relationship between plasma antipsychotic drug concentration, serum prolactin levels and the clinical efficacy of risperidone, 2) the relationship between the CYP2D6 polymorphisms and metabolizing of risperidone and 3) the role of 9-hydroxyrisperidone in elevating prolactin levels. One-hundred and eighteen Chinese schizophrenia patients (40 males, 78 females, age 15—60 years) were given risperidone at dosages ranging from 2—8 mg/day for 8 weeks. Clinical efficacy was determined using the Brief Psychiatric Rating Scores (BPRS). Serum prolactin levels were assayed before and after the 8 week treatment and plasma risperidone and 9-hydroxyrisperidone levels were also measured at the end of the 8-week treatment. The results showed there was no significant correlation between the concentration of active moiety and clinical response. Risperidone treatment significantly increased serum prolactin levels. Furthermore, changes of prolactin levels were not correlated with the clinical response. For the risperidone/ 9-hydroxyrisperidone ratio, there was a statistically significant difference among the CYP2D6*1/*1, *1/*10, *10/*10 genotypes (Kruskal—Wallis test, p = 0.012). No significant differences were found in the concentration of 9-hydroxyrisperidone and active moiety among the genotypes. In addition, the concentration of 9-hydroxyrisperidone was not significantly correlated with the increase of serum prolactin. In conclusion, our study has, for the first time, produced evidence that in Chinese schizophrenic patients, the metabolism of risperidone is dependent on CYP2D6. Neither changes in serum prolactin levels nor plasma concentration of active moiety were significantly correlated with clinical efficacy of risperidone. 9-hydroxyrisperidone may not play a predominant role in elevating serum prolactin level.

Key Words: schizophrenia • CYP2D6 • clinical response • prolactin • risperidone • 9-hydroxyrisperidone

References

  • Bondolfi G., Dufour H., Patris M., May J.P., Billeter U., Eap C.B., Baumann P. (1998) Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry 155: 499—504[Abstract/Free Full Text]
  • Chou J.C., Douyon R., Czobor P., Volavka J., Cooper T.B. (1998) Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder. Psychiatry Res 81: 51—55[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Chouinard G., Arnott W. Clinical review of risperidone (1993) Can J Psychiatry 38(Suppl 3): S89—S95[Web of Science][Medline] [Order article via Infotrieve]
  • David S.R., Taylor C.C., Kinon B.J., Breier A. (2000) The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 22: 1085—1096[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Douglas A.M., Atchison B.A., Somogyi A.A., Drummer O.H. (1994) Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism. Pharmacogenetics 4: 154—158[Web of Science][Medline] [Order article via Infotrieve]
  • Fang J., Bourin M., Baker G.B. (1999) Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 359: 147—151[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Heim M., Meyer U.A. (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336: 529—532[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hersberger M., Marti-Jaun J., Rentsch K., Hanseler E. (2000) Rapid detection of the CYP2D6*3, CYP2D6*4 and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin Chem 46: 1072—1077[Abstract/Free Full Text]
  • Huang M.L., Van Peer A., Woestenborghs R., De Coster R., Heykants J., Jansen A.A., Zylicz Z., Visscher H.W., Jonkman J.H. (1993) Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 54: 257—268[Web of Science][Medline] [Order article via Infotrieve]
  • Kapur S., Roy P., Daskalakis J., Remington G., Zipursky R. (2001) Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am J Psychiatry 158: 311—314[Abstract/Free Full Text]
  • Knegtering R., Baselmans P., Castelein S., Bosker F., Bruggeman R., Van den Bosch R.J. (2005) Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 162: 1010—1012[Abstract/Free Full Text]
  • Lee B.H., Kim Y.K. (2006) The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients. Prog Neuropsychopharmacol Biol Psychiatry 30: 658—662[CrossRef][Medline] [Order article via Infotrieve]
  • Lee H.S., Tan C.H., Khoo Y.M., Chee K.T., Wong K.E., Chong S.A., Mahendran R., Yap J.L., Low B.L., Choo C.H., Chan A. ( 1999) Serum concentrations and clinical effects of risperidone in schizophrenic patients in Singapore—a preliminary report. Br J Clin Pharmacol 47: 460—461[Web of Science][Medline] [Order article via Infotrieve]
  • Leysen J.E., Gommeren W., Eens A., De Chaffoy D.C., Stoof J.C., Janssen P.A. (1998) Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247: 661—670
  • Markianos M., Hatzimanolis J., Lykouras L. (1999) Gonadal axis hormones in male schizophrenic patients during treatment with haloperidol and after switch to risperidone. Psychopharmacology (Berl) 143: 270—272[CrossRef][Medline] [Order article via Infotrieve]
  • Matsubara Y., Ohnuma T., Shibata N., Takahashi T., Arai H. ( 2002) Plasma concentration of risperidone showed a correlation with daily dose, but not with age nor cytochrome P-450 2D6 gene polymorphisms in Japanese schizophrenics. Psychogeriatrics 2: 284—288[CrossRef]
  • Mauri M.C., Laini V., Boscati L., Rudelli R., Salvi V., Orlandi R., Papa P. ( 2001) Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels. Eur Psychiatry 16: 57—63[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Meltzer H.Y., Busch D.A., Fang V.S. (1983) Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response. Psychiatry Res 9: 271—283[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mihara K., KondoT., Yasui-Furukori N., Suzuki A., Ishida M., Ono S., Kubota T., Iga T., Takarada Y., De Vries R., Kaneko S. (2003) Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia. Ther Drug Monit 25: 287—293[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Olesen O.V., Linnet K. (1997) Simplified high-performance liquid chromatographic method of determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs. J Chromatogr B 698: 209—216[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Olesen O.V., Licht R.W., Thomsen E., Bruun T., Viftrup J.E., Linnet K. (1998) Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit 20: 380—384[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Overall J.E., Gorham D.R. (1962) The brief psychiatric rating scale. Psychol Rep 10: 799—812[Web of Science]
  • Roh H.K., Dahl M.L., Johansson I., Ingelman-Sundberg M., Cha Y.N., Bertilsson L. (1996) Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 6: 441—447[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Roh H.K., Kim C.E., Chung W.G., Park C.S., Svensson J.O., Bertilsson L. (2001) Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. Eur J Clin Pharmacol 57: 671—675[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Shingo K., Reiji Y., Koji S., Chima M., Makiko G., Kyoko K., Yasuhisa Y., Nobuhisa U., Osamu O., Jun N. ( 2005) Prediction of response to risperidone treatment with respect to plasma concentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6. Int Clin Psychopharmacol 20: 71—78[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Scordo M.G., Spina E., Facciola G., Avenoso A., Johansson I., Dahl M.L. (1999) Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl) 147: 300—305[CrossRef][Medline] [Order article via Infotrieve]
  • Spina E., Avenoso A., Facciola G., Salemi M., Scordo M.G., Ancione M., Madia A.G., Perucca E. (2001) Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology (Berl) 153: 238—243[CrossRef][Medline] [Order article via Infotrieve]
  • van Beijsterveldt L.E., Geerts R.J., Leysen J.E., Megens A.A., Van den Eynde H.M., Meuldermans W.E., Heykants J.J. (1994) Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology (Berl) 114: 53—62[CrossRef][Medline] [Order article via Infotrieve]
  • Van Putten T, Marder S.R., Mintz J. (1991) Serum prolactin as a correlate of clinical response to haloperidol. J Clin Psychopharmacol 11: 357—361[Web of Science][Medline] [Order article via Infotrieve]
  • Xie H.G., Kim R.B., Wood A.J., Stein C.M. (2001) Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 41: 815—850[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yasui-Furukori N., Mihara K., Kondo T., Kubota T., Iga T., Takarada Y., De Vries R., Kaneko S., Tateishi T. (2003) Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia. J Clin Pharmacol 43: 122—127[Abstract/Free Full Text]
  • Zhang X.Y., Zhou D.F., Yuan C.L., Zhang P.Y., Wu G.Y., Shen Y.C. (2002) Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia. Psychiatry Res 109: 297—302[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

This version was published on November 1, 2007

Journal of Psychopharmacology, Vol. 21, No. 8, 837-842 (2007)
DOI: 10.1177/0269881107077357
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Wang, L.
Right arrow Articles by He, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, L.
Right arrow Articles by He, L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement